Far from it. This board is hand picked by NP and Dr Kelly is chairman. This board is not going to replace the management. The acquisition of Cytodyn by a large Pharma will make the point mute. The first EUA is the next trigger for significant stock allocations per NP from a conference call late last year. . And when they get the first EUA they will all deserve major shares. It’s hard for a small Pharma to get over the hump. The partnerships with big Pharma to help sell and market Virologix will be potential buyout candidates. But I’m still thinking Abbvie is the best partner/acquisition company . They need a blockbuster drug to replace Humira and that is off patent in the US in 2023.